Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease.

ABSTRACT:

Aims

To assess whether the use of beta-blockers influences mortality and the incidence of major cardiovascular events in patients with diabetes and coronary heart disease (CHD).

Materials and methods

Using data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial, we performed Cox proportional hazards analysis to assess the effects of β-blockers on all-cause mortality in 2244 patients with type 2 diabetes who had stable CHD with and without a history of myocardial infarction (MI)/heart failure with reduced left ventricular ejection fraction (HFrEF).

Results

All-cause mortality in patients with MI/HFrEF was significantly lower in those receiving β-blockers than in those not receiving β-blockers (adjusted hazard ratio [HR] 0.60, 95% confidence in

SUBMITTER: Tsujimoto T 

PROVIDER: S-EPMC5484336 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature